Abstract |
The N-terminal substance P fragment SP(1-7) is known to modulate hyperalgesia and opioid withdrawal in animal models. This study examined the effects of intraperitoneal (i.p.) injections of SP(1-7) on chronic morphine tolerance and on the levels of dynorphin B (DYN B) and nociceptin/orphanin FQ (N/OFQ) in various brain areas of male Sprague-Dawley rats. Morphine tolerance was induced by subcutaneous injections of the opioid (10mg/kg) twice daily for 7 days. SP(1-7) injected i.p. (185 nmol/kg) 30 min prior to morphine reduced the development of morphine tolerance. Immunoreactive (ir) DYN B and N/OFQ peptide levels were measured in several areas of the central nervous system. Levels of ir DYN B in rats treated with SP(1-7) and morphine were decreased in the nucleus accumbens, substantia nigra and ventral tegmental area and increased in the frontal cortex. The ir N/OFQ levels were increased in the periaqueductal gray and decreased in the nucleus accumbens. Since the concentration profiles of the two peptides were altered by SP(1-7) in the areas that are implicated in the modulation of opioid tolerance and analgesia, it is suggested that DYN B and N/OFQ systems may be involved in the effects of SP(1-7) on opioid tolerance.
|
Authors | Qin Zhou, Anna Carlsson, Mathias Hallberg, Fred Nyberg |
Journal | Peptides
(Peptides)
Vol. 32
Issue 8
Pg. 1661-5
(Aug 2011)
ISSN: 1873-5169 [Electronic] United States |
PMID | 21763376
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Inc. All rights reserved. |
Chemical References |
- Analgesics, Opioid
- Endorphins
- Opioid Peptides
- Peptide Fragments
- Substance P
- substance P (1-7)
- Dynorphins
- Morphine
- nociceptin
- rimorphin
|
Topics |
- Analgesics, Opioid
(pharmacology)
- Animals
- Drug Tolerance
- Dynorphins
(pharmacology)
- Endorphins
(pharmacology)
- Male
- Morphine
(pharmacology)
- Opioid Peptides
(pharmacology)
- Pain Measurement
- Peptide Fragments
(pharmacology)
- Rats
- Rats, Sprague-Dawley
- Substance P
(pharmacology)
|